A carregar...
Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer
BACKGROUND: Ovarian cancer represents the most fatal type of gynecological malignancies. Unfortunately, there are still no effective targeted treatment strategies for ovarian cancer. Overexpression of CRM1 has been correlated with poor prognosis of patients with ovarian cancer. AIM: In this study, w...
Na minha lista:
| Publicado no: | J Ovarian Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4465006/ https://ncbi.nlm.nih.gov/pubmed/26055813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-015-0166-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|